The latest Chair's Report elucidates how the Surgical Oncology team is reducing mortality rates for abdominal cancers and researching disparities in treating hepatocellular (liver) cancer. Learn more
Hyperthermic Intraperitoneal Chemoperfusion (HIPEC)
Mount Sinai is the site of one of the busiest Hyperthermic Intraperitneal Chemoperfusion (HIPEC) programs in the country. Our Surgical Oncology team at has performed nearly 250 HIPEC procedures. This technique, which combines surgery with chemotherapy, has revolutionized the treatment of cancers in the abdominal lining.
HIPEC delivers heated chemotherapy directly into the abdominal cavity, where it penetrates the diseased tissue directly. The hyperthermia further increases absorption of the chemotherapy solution into tumor cells. Because HIPEC allows the chemotherapy to be delivered directly to the site, the side effects of intravenous chemotherapy are eliminated. Additionally, it destroys undetected cancer cells after the tumor has been removed, preventing them from forming into new tumors and causing a recurrence of cancer.
"Abdominal cancers have historically been difficult to treat," notes Daniel Labow, MD, Chair for the Department of Surgery at Mount Sinai St. Luke’s and Mount Sinai West. "But the HIPEC combination procedure has proven to significantly extend patient survival rates."
Mount Sinai Surgical Associates
Division of Surgical Oncology
1470 Madison Ave, 3rd Fl
New York, NY 10029
Victoria Murphy went to Mount Sinai for a second opinion for treating her appendiceal cancer. Read More
CBS 2's Dr. Max Gomez takes a look at how doctors at Mount Sinai are fighting cancer. View Now